Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors

被引:1
|
作者
Pinto, Patricia [1 ]
Shetty, Shrimati [1 ]
Lacroix-Desmazes, Sebastien [2 ,3 ,4 ,5 ,6 ]
Bayry, Jagadeesh [2 ,3 ,4 ,5 ,6 ]
Kaveri, Srini [2 ,3 ,4 ,5 ,6 ]
Ghosh, Kanjaksha [1 ]
机构
[1] Natl Inst Immunohaematol ICMR, 13th Floor,New Multistoreyed Bldg,KEM Hosp Campus, Bombay 400012, Maharashtra, India
[2] Ctr Rech Cordeliers, INSERM, UMRS 1138, Paris, France
[3] Univ Paris 06, UMRS 1138, Paris, France
[4] Univ Paris 05, UMRS 1138, Paris, France
[5] Lab Int Assoc INSERM, Paris, France
[6] ICMR, Paris, France
关键词
Haemophilia A; FVIII; Inhibitors; Autoantibodies; India; FACTOR-VIII INHIBITORS; PREVIOUSLY UNTREATED PATIENTS; RECOMBINANT FACTOR-VIII; RISK-FACTORS; ACQUIRED HEMOPHILIA; LUPUS ANTICOAGULANT; FACTOR-IX; HEPATITIS-C; EFFICACY; MARKERS;
D O I
10.1016/j.imlet.2015.09.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diagnosis and management of haemophilia patients with inhibitors is often tricky due to the heterogeneous nature of the antibodies with regard to their kinetics, as well as the co-existence of other interfering antibodies. Plasma samples from severe haemophilia A patients from India with and without FVIII inhibitors were analysed for the presence of possible co-existing antibodies such as lupus anticoagulants (LA), anti-cardiolipin antibodies (ACLA), anti-132-glycoprotein-I (anti-beta 2-GP-I) antibodies, viral transfusion transmitted disease (HIV, HBsAg, HCV) related antibodies, anti-cyclic citrullinated peptides (anti-CCP), and anti-nuclear antibodies. A high incidence of LA and anti-HCV antibodies was detected in Indian haemophilia A patients similar to earlier reports. More importantly, a relatively high incidence of autoantibodies to nuclear antigens (18.62%) and anti-CCP antibodies (1.38%) associated with autoimmune disorders was also seen in these congenital haemophilia A patients with and without inhibitors. Knowledge on the antibody profile in these haemophilia patients especially in those with FVIII inhibitors along with correlation with the clinical manifestations and other risk factors for inhibitor development could possibly shed more light on the complex immune response in these patients. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 50 条
  • [41] HAVEN 2: Emicizumab Prophylaxis for Children with Haemophilia A with FVIII Inhibitors
    Young, G.
    Liesner, R.
    Sidonio, R.
    Oldenburg, J.
    Jimenez-Yuste, V.
    Malangu, J.
    Kruse-Jarres, R.
    Wang, M.
    Chang, T.
    Uguen, M.
    Doral, M.
    Schmitt, C.
    Levy, G.
    Shima, M.
    Mancuso, M. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 30 - 31
  • [42] Inhibitors in haemophilia A: the role of VWF/FVIII concentrates - a meeting report
    Kaveri, S.
    Gringeri, A.
    Heisel-Kurth, M.
    Kreuz, W.
    HAEMOPHILIA, 2009, 15 (02) : 587 - 591
  • [43] QUALITATIVE RESEARCH EXPLORING LIFE CHANGES IN PATIENTS LIVING WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS TREATED WITH EMICIZUMAB
    Volot, F.
    Lambert, T.
    Harroche, A.
    Derlon, A. B.
    Guerin, N.
    Castet, S.
    Hadim, F.
    Gaude, A.
    Tugaut, B.
    Michel, A. -S.
    Guillet, B.
    HAEMOPHILIA, 2023, 29 : 195 - 195
  • [44] HLA genotype of patients with severe haemophilia a due to intron 22 inversion with and without inhibitors of factor VIII
    Oldenburg, J
    Picard, JK
    Schwaab, R
    Brackmann, HH
    Tuddenham, EGD
    Simpson, E
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (02) : 238 - 242
  • [45] Patients' preferences for FVIII reconstitution devices in haemophilia A
    Di Minno, G.
    Halimeh, S.
    Westfeld, M.
    HAEMOPHILIA, 2013, 19 : 68 - 68
  • [46] Effectiveness of starting emicizumab in routine clinical practice for patients with severe haemophilia A without FVIII inhibitor: Results using PicnicHealth data in the US
    Pipe, Steven
    Sharma, Narayan
    Siadimas, Athanasios
    Liao, Noelle
    Hanson, Gillian
    Chafaie, Romain
    Moreno, Katya
    Biondo, Juliana
    Polito, Letizia
    HAEMOPHILIA, 2024, 30 : 138 - 139
  • [47] Tertiary prophylaxis in patients with haemophilia A and FVIII inhibitor
    Smejkal, P.
    Romanova, G.
    Polak, P.
    Penka, M.
    HAEMOPHILIA, 2019, 25 : 157 - 157
  • [48] FVIII inhibitor epitope mapping in haemophilia A patients
    Moret, A.
    Haya, S.
    Quintana, M.
    Jimenez-Yuste, V
    Altisent, C.
    Parra, R.
    Perez, R.
    Lopez, M. F.
    Gimenez, F.
    Malcorra, J. J.
    Paloma, M. J.
    Prieto, M.
    Sedano, C.
    Soto, I
    Gutierrez, M. J.
    Cortina, V
    Galmes, B.
    Canaro, M.
    Aznar, J. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 519 - 520
  • [49] GENETIC PREDICTORS FOR FVIII INHIBITORS DEVELOPMENT IN GREEK PAEDIATRIC POPULATION WITH SEVERE HAEMOPHILIA A EXCLUSIVELY TREATED WITH RECOMBINANT CONCENTRATES
    Pergantou, H.
    Kapsimali, Z.
    Spanou, K.
    Varela, I.
    Michalopoulou, A.
    Dettoraki, A.
    Economou, M.
    Constantinidou, N.
    Kanariou, M.
    Platokouki, H.
    HAEMOPHILIA, 2020, 26 : 33 - 34
  • [50] Inhibitors in children with severe haemophilia A treated with recombinant and plasmatic FVIII products A hypothesis-based cumulative metaanalysis
    Halimeh, S.
    Bidlingmaier, C.
    Brandao, L. R.
    Ettingshausen, C. Escuriola
    Holzhauer, S.
    Kenet, G.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Nowak-Goettl, U.
    HAMOSTASEOLOGIE, 2010, 30 (4A): : S141 - S145